<DOC>
	<DOCNO>NCT03048877</DOCNO>
	<brief_summary>Radioactive iodine-refractory differentiate thyroid cancer ( RAIR-DTC ) great challenge treatment thyroid cancer . Tyrosine kinase inhibitor ( TKIs ) , like sorafenib lenvatinib approve food drug administration ( FDA ) , could affordable Chinese patient . Apatinib highly selective VEGFR2 inhibitor reduces angiogenesis tumor efficiently , proven effective many solid tumor , Chinese domestic TKI target vascular endothelial growth factor receptor ( VEGFR ) . A phase II study aim assess efficacy safety apatinib RAIR-DTC enrol 20 patient , 10 obtain shout-term efficacy , study demonstrate peculiar potential treatment RAIR-DTC . In study , investigator aim explore efficacy safety apatinib RAIR-DTC .</brief_summary>
	<brief_title>Efficacy Apatinib Radioactive Iodine-refractory Differentiated Thyroid Cancer</brief_title>
	<detailed_description>Primary Outcome Measure : Progression free survival apatinib RAIR-DTC . Secondary Outcome Measures : Disease control rate , objective response rate , duration response , change Tg TgAb level serum , overall survival , side effect quality life .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>1 . Aged 18 year ( 18 include ) . 2 . Locally advanced metastatic differentiate thyroid cancer ( papillary , follicular , Hurthle cell , poorly differentiate carcinoma ) . At least one measurable lesion ( helical CT scan long diameter ≥10mm , meet requirement standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1 ) . 3 . Disease progression within 12 month inclusion . 4 . Subjects must 131Irefractory / resistant define least one follow ; Lesions demonstrate iodine uptake radioiodine scan ; Subjects receive single radioactive iodine therapy within 12 month ( ≥ 3.7 Giga Bequerel（GBq） [ ≥ 100 millicurie（mCi） ] ) target lesion disease progression ; Every two radioactive iodine treatment interval &lt; 12 month , dose ≥ 3.7 GBq [ ≥100mCi ] , disease progress 12 month least iodine therapy ; Received total dose radioactive iodine therapy ≥ 22.2 GBq ( ≥ 600 mCi ) ; 5 . Normal main organ function : HB ≥ 90g / L ; ANC ≥1.5×109/L ; PLT ≥80×109/L ; BIL &lt; 1.5 × ULN ; ALT AST &lt; 2.5 × ULN ; Cr≤1×ULN ; 6 . Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :02 . 7 . An expected survival ≥ 3 month . 8 . Pregnancy test ( serum ) perform woman childbearing age within 7 day enrolment test result must negative . They shall take appropriate method contraception study 8th week post last administration study drug . For men , ( previous surgical sterilization accept ) , shall agree take appropriate method contraception study 8th week post last administration study drug . 9 . Patient voluntarily join study sign Informed Consent Form study . 10 . Good compliance expect , accord program requirement followup record adverse reaction . 1 . Other thyroid cancer histological subtypes ( medullary carcinoma , lymphoma sarcoma ) . 2 . Received VEGFR inhibitor ( vandetanib , cabozantinib , lenvatinib , sunitinib , sorafenib , etc . ) treatment within 1 month . 3 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; coronary heart disease great Class II ; IIlevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class II cardiac dysfunction . 4 . Factors could effect oral medication ( inability swallow , nausea , vomit , chronic diarrhea intestinal obstruction ) . 5 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 3 month . 6 . Abnormal Coagulation ( INR &gt; 1.5、APTT &gt; 1.5 UNL ) , tendency bleed . 7 . Disposition evidence thrombosis/bleeding 2 month ( despite severity ) , hemoptysis 2 month ( bright red blood , 1/2 teaspoon ) . 8 . Arterial /venous thromboembolic event , cerebrovascular accident , deep vein thrombosis pulmonary embolism past 12 month . 9 . Factors could receive radiotherapy major surgery anti thyroid cancer past 28 day . 10 . Factors could receive surgery ( allow fullrecovery wound ) active hemorrhage , ulceration , intestinal perforation intestinal obstruction past 28 day . 11 . Uncontrolled infection . 12 . Pregnant lactating woman . 13 . Disposition evidence depressive disorder ( HAMD score ≥17 ) . 14 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radioactive iodine-refractory</keyword>
	<keyword>differentiate thyroid cancer</keyword>
	<keyword>Apatinib</keyword>
	<keyword>anti-angiogenesis drug</keyword>
</DOC>